#insulin4all USA
Opinion: The insulin crisis is far from over
16 Oct 2024, 6:08 p.m. in #insulin4all USA, News & Statements by Arden Parrish
This blog post was first published in the Hartford Courant on September 15, 2024 by Arden Parrish under the title: Opinion: The insulin crisis is far from over. Public pharma could be the solution. Read more
The movement for public insulin production continues to grow in the United States
12 Jun 2024, 7:40 p.m. in #insulin4all USA, News & Statements by Quinn Nichols, Nicole Koonce, and Allison Hardt
This blog post was first published in Bridge Michigan on May 28, 2024 by Quinn Nichols, Nicole Koonce, and Allison Hardt under the title: Michigan has a chance to learn from California’s public pharma initiative. Read more
Insulin Shortages: a policy choice with policy solutions
8 May 2024, 4:38 p.m. in #insulin4all USA, Global Stories, Interviews by Shaina Kasper, Policy & Advocacy Director, T1International
Over the past few months, people with type 1 diabetes around the globe have been going from pharmacy to pharmacy in search of insulin. There have been insulin shortages in many different countries. For people living with type 1 diabetes, insulin is as important as oxygen and people need a consistent supply. Insulin shortages can lead to irreversible complications and even death. Read more
Open letter to WHO calling for urgent action on meaningful patient engagement
2 May 2024, 6:41 p.m. in #insulin4all USA, News & Statements by T1International
We are writing to propose WHO action items aimed at addressing meaningful engagement with people living with diabetes in the global coverage targets for diabetes. Read more
T1International Invited to White House Event
22 Apr 2024, 6:21 p.m. in #insulin4all USA, News & Statements by T1International
T1International advocates, Jesús Morales Sánchez (Communities of Color Working Group Co-Leader), Kristen Whitney Daniels (Federal Working Group Co-Leader), Lib Gatti (USA Advocacy Manager), and Shaina Kasper (Policy and Advocacy Director), were honored to be invited to a recent event at the White House focused on lowering healthcare costs. The event celebrated the success of the access to medicines movement in achieving a $35 monthly cap on out-of-pocket costs for insulin for Medicare Part D beneficiaries, allowing Medicare to negotiate drug prices directly with pharmaceutical companies, and more. Read more
Global Day of Action for #insulin4all demands insulin equity NOW
21 Mar 2024, 3:50 p.m. in #insulin4all USA, Global Stories, News & Statements by T1International
On March 16, 2024, hundreds of #insulin4all advocates participated in over a dozen events across the globe calling for insulin access and affordability as part of the Global Day of Action for #insulin4all, sharing their stories on the critical need for insulin equity now. Read more
A Note from T1International’s New Board Chair about T1International’s Impact
27 Feb 2024, 1:08 p.m. in #insulin4all USA, Interviews, News & Statements by Melissa Passarelli
As a person living with type 1 diabetes who has been involved with T1International since 2019, I’m so proud to step into the role of Board Chair of Trustees this year. I believe in this organisation and this cause deeply because it is personal to me. I live with the ups and downs of diabetes, and I believe in health justice for everyone who is faced with this condition worldwide. Read more
Promised Price Cuts Not Cutting It: There is No $35 Price Cap on Insulin
11 Jan 2024, 5:16 p.m. in #insulin4all USA, News & Statements by T1International
The #insulin4all movement has had some major victories lately. For example, Medicare beneficiaries can access $35 copays for some insulins. The list price of insulin went down for nine insulins. Over half of the states in the USA have passed some form of insulin copay cap. These victories were hard fought by #insulin4all advocates over the past decade. But we’re not celebrating the much heralded $35 insulin cap for all. Because it’s not true.
Read more
Levemir Discontinuation Impacts Patients
8 Dec 2023, 1:04 p.m. in #insulin4all USA, News & Statements
Only eight days of National Diabetes Awareness Month had passed this November when pharmaceutical company Novo Nordisk announced it would be pulling Levemir, a long-acting insulin that millions of insulin-dependent diabetic patients depend on, from the U.S. market. Read more
T1International 2023 Summit: Advocacy in Action
30 Sep 2023, 10:31 p.m. in #insulin4all USA, Global Stories by Fiona Conner
As I listened to the amazing sessions at this year's Summit, the rage from 2016 was still there, and rightly so, but there was also so much love, inclusivity and power. Whether you like the term 'patients' or not - we debated it at the Summit - this event was full of patients taking back their power. I was proud to be part of it and continue to be proud that T1International is making such a huge global impact as a small, pharma-free charity. Read more